Literature DB >> 2751270

Chemosensitivity and multidrug resistance to antineoplastic drugs in retinoblastoma cell lines.

H S Chan1, M D Canton, B L Gallie.   

Abstract

Chemosensivity testing in 11 retinoblastoma (RB) cell lines identified five tumors showing cross-resistance to plant alkaloids, alkylating agents, anthracycline antibiotics, and antimetabolites, suggestive of the multidrug-resistant (MDR) phenotype described in other tumors. Only two tumors had been clinically exposed to chemotherapy, and both showed MDR. All RB tumors were resistant to clinically achievable concentrations of methotrexate and hydrocortisone, and only sensitive to cytosine arabinoside. These results provide a rational basis on which to develop new chemotherapeutic strategies for the treatment of RB.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2751270

Source DB:  PubMed          Journal:  Anticancer Res        ISSN： 0250-7005            Impact factor:   2.480


  10 in total

Review 1.  Chemotherapy for retinoblastoma: a current topic.

Authors:  P T Finger; G Czechonska; H Demirci; A Rausen
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  In vitro evaluation of a targeted and sustained release system for retinoblastoma cells using Doxorubicin as a model drug.

Authors:  Sai H S Boddu; Jwala Jwala; Monica R Chowdhury; Ashim K Mitra
Journal:  J Ocul Pharmacol Ther       Date:  2010-10       Impact factor: 2.671

3.  Evaluation of cytotoxicity and mechanism of apoptosis of doxorubicin using folate-decorated chitosan nanoparticles for targeted delivery to retinoblastoma.

Authors:  Suphiya Parveen; Sanjeeb K Sahoo
Journal:  Cancer Nanotechnol       Date:  2010-10-25

Review 4.  Multidrug resistance in pediatric oncology.

Authors:  J F Kuttesch
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

5.  Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines.

Authors:  W Li; J Fan; D Hochhauser; D Banerjee; Z Zielinski; A Almasan; Y Yin; R Kelly; G M Wahl; J R Bertino
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

Review 6.  Current management strategies for intraocular retinoblastoma.

Authors:  Jonathan W Kim; David H Abramson; Ira J Dunkel
Journal:  Drugs       Date:  2007       Impact factor: 9.546

7.  Basic fibroblast growth factor impact on retinoblastoma progression and survival.

Authors:  Colleen M Cebulla; Maria-Elena Jockovich; Yolanda Piña; Hinda Boutrid; Armando Alegret; Amy Kulak; Abigail S Hackam; Sanjoy K Bhattacharya; William J Feuer; Timothy G Murray
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-07-09       Impact factor: 4.799

8.  Multidrug resistant proteins: P-glycoprotein and lung resistance protein expression in retinoblastoma.

Authors:  S Krishnakumar; K Mallikarjuna; N Desai; A Muthialu; N Venkatesan; A Sundaram; V Khetan; M P Shanmugam
Journal:  Br J Ophthalmol       Date:  2004-12       Impact factor: 4.638

9.  Expression of P-glycoprotein in human retinoblastoma and its clinical significance.

Authors:  Sumita Sethi; Manzoor Ahmad Malik; Sandeep Goswami; Parul Saxena; Arpna Srivastava; Seema Kashyap; Neelam Pushker; Mandeep Singh Bajaj; Sameer Bakhshi; Jasbir Kaur
Journal:  Tumour Biol       Date:  2014-08-31

10.  Combined treatment with an oncolytic adenovirus and antitumor activity of vincristine against retinoblastoma cells.

Authors:  Xin Song; Haibo Wang; Renbing Jia; Biyun Cun; Xiaoping Zhao; Yixiong Zhou; Xiaofang Xu; Guanxiang Qian; Shengfang Ge; Xianqun Fan
Journal:  Int J Mol Sci       Date:  2012-08-27       Impact factor: 6.208
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.